Trial Profile
Safety and efficacy of oral AGN 203818 for the relief of irritable bowel syndrome pain.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2012
Price :
$35
*
At a glance
- Drugs Rezatomidine (Primary)
- Indications Visceral pain
- Focus Therapeutic Use
- 19 Jan 2012 Planned end date changed from 1 Apr 2010 to 1 Feb 2008 as reported by ClinicalTrials.gov
- 19 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
- 20 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.